Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewINCB 024360-analog is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50 values are 19 and 67 nM in enzymatic activity and HeLa cell assays, respectively). Decreases kynurenine levels in plasma and reduces tumor growth in vivo. Cell membrane permeable.
INCB 024360-analog is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 271.64 |
Formula | C9H7ClFN5O2 |
Storage | Store at -20°C |
Purity | ≥99% (HPLC) |
CAS Number | 914471-09-3 |
PubChem ID | 11978742 |
InChI Key | MUVQOOPKPBEAJZ-VQHVLOKHSA-N |
Smiles | O/N=C(NC1=CC(Cl)=C(F)C=C1)/C2=NON=C2N |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 27.16 | 100 | |
ethanol | 27.16 | 100 |
The following data is based on the product molecular weight 271.64. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.68 mL | 18.41 mL | 36.81 mL |
5 mM | 0.74 mL | 3.68 mL | 7.36 mL |
10 mM | 0.37 mL | 1.84 mL | 3.68 mL |
50 mM | 0.07 mL | 0.37 mL | 0.74 mL |
References are publications that support the biological activity of the product.
Weinmann (2016) Cancer immunotherapy: selected targets and small-molecule modulators. Chem.Med.Chem. 11 450 PMID: 26836578
Yue et al (2009) Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J.Med.Chem. 52 7364 PMID: 19507862
Dounay et al (2015) Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J.Med.Chem. 58 8762 PMID: 26207924
If you know of a relevant reference for INCB 024360-analog, please let us know.
Keywords: INCB 024360-analog, INCB 024360-analog supplier, 1, Indoleamine, 2,3-dioxygenase, IDO, inhibitors, inhibits, cancer, immunology, 2,3, dioxygenase, Immune, Checkpoints, 6007, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for INCB 024360-analog. Do you know of a great paper that uses INCB 024360-analog from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review INCB 024360-analog and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.